JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $27.
JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $27.